Turkish Journal of Hematology Volume: 33 - Issue: 4

More documents

Recommendations

Info

Turk J Hematol 2016;33:265-272 Kesik V, et al: Prognostic Markers of Hodgkin’s Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Treatment Results The median (mean ± standard deviation, minimum-maximum) level of lymphocyte counts at day 15 after AHSCT was 0.45x10 3 / µL (0.51±0.38x10 3 /µL, 0.01-1.8). The median (mean ± standard deviation, minimum-maximum) levels of WBCs, lymphocytes, neutrophils, monocytes, platelets, and MPV at day 100 after AHSCT were 3.9x10 3 /µL (4.6±2.7x10 3 /µL, 1.2-14.6), 1.3x10 3 / µL (1.4±0.9x10 3 /µL, 0.02-5.1), 1.9x10 3 /µL (2.5±2.3x10 3 /µL, 0.3- 12.4), 0.36x10 3 /µL (0.41±0.27x10 3 /µL, 0.04-1.43), 127x10 3 / µL (131±80x10 3 /µL, 14-308), and 7.5 fL (7.7±1.4 fL, 4.9-11.3), respectively. Three-year OS/PFS rates were 77.3% and 68.5% with a median follow-up of 27 months (minimum-maximum: 1-114 months) for all patients, respectively. The prognostic factors affecting EFS and OS are presented in Tables 2 and 3. of 2 (p=0.36), while the 3-year OS rates were 80.0% for a score of 0 (death due to infection), 93.3% for a score of 1, and 75.0% for a score of 2 (p=0.46) (Figure 1). Patients were scored based on a WBC count of >10x10 3 /µL at 100 days after AHSCT (0: no, 1: yes), RT before AHSCT (0: yes, 1: no), remission status at AHSCT (0: yes, 1: no), PET-CT status at 100 days after AHSCT (0: negative, 1: positive), and serum albumin of
Kesik V, et al: Prognostic Markers of Hodgkin’s Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Turk J Hematol 2016;33:265-272 the following 3-year PFS rates: Group 0=100%, Group 1=66.7%, Group 2=50%, and Group >3=0% (p=0.001) (0: low risk, 1: lowintermediate risk, 2: high-intermediate risk, >3: high risk). For 3-year OS, remission status at AHSCT (0: yes, 1: no), relapse after AHSCT (0: no, 1: yes), and bone marrow positivity at diagnosis (0: no, 1: yes) were scored and showed that Group 0=92%, Group 1=78.6%, and Group 2=40% (p10x10 3 /µL, posttransplant PET positivity at day 100, serum albumin of
Page 1 and 2: Volume 33 Issue 4 December 2016 80
Page 3 and 4: Contact Information Editorial Corre
Page 5 and 6: TURKISH JOURNAL OF HEMATOLOGY INSTR
Page 7 and 8: should include a conclusion, in whi
Page 9 and 10: as appropriate, and then click the
Page 11 and 12: 335 Evaluation of Insulin-like Grow
Page 13 and 14: 6 th International Congress on Leuk
Page 15 and 16: Kesik V, et al: Prognostic Markers
Page 17: Kesik V, et al: Prognostic Markers
Page 21 and 22: Kesik V, et al: Prognostic Markers
Page 23 and 24: Tombak A, et al: Azacitidine and El
Page 31 and 32: Malkan ÜY, et al: The Prognosis of
Page 33 and 34: Malkan ÜY, et al: The Prognosis of
Page 35 and 36: RESEARCH ARTICLE DOI: 10.4274/tjh.2
Page 37 and 38: Ghasemi M, et al: Identification of
Page 43 and 44: Yorulmaz G, et al: Hyperparathyroid
Page 49 and 50: Kahlon P, et al: Therapeutic Intern
Page 51 and 52: Kahlon P, et al: Therapeutic Intern
Page 53 and 54: RESEARCH ARTICLE DOI: 10.4274/tjh.2
Page 55 and 56: Işlak Mutcalı S, et al: Early Cha
Page 61 and 62: Çalık Başaran N, et al: Infectio
Page 69 and 70:
RESEARCH ARTICLE DOI: 10.4274/tjh.2
Page 71 and 72:
Terzi YK, et al: HFE Mutations and
Page 73 and 74:
Terzi YK, et al: HFE Mutations and
Page 75 and 76:
RESEARCH ARTICLE DOI: 10.4274/tjh.2
Page 77 and 78:
Baytan B, et al: Emotional Status a
Page 79 and 80:
Baytan B, et al: Emotional Status a
Page 81 and 82:
Ishibashi M, et al: CBFA2T3-GLIS2 F
Page 83 and 84:
Ishibashi M, et al: CBFA2T3-GLIS2 F
Page 85 and 86:
Ayer M, et al: Evaluation of IGF-1
Page 87 and 88:
Ayer M, et al: Evaluation of IGF-1
Page 89 and 90:
Patıroğlu T and Akar HH; HLA (A,
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
BRIEF REPORT DOI: 10.4274/tjh.2016.
Page 97 and 98:
Düzgöl M, et al: Varicella Infect
Page 99 and 100:
Jain M, et al. Chediak-Higashi Synd
Page 101 and 102:
Pradhan S: Auer Rod-Like Inclusions
Page 103 and 104:
Milosevic I: Coexistence of Chronic
Page 105 and 106:
LETTERS TO THE EDITOR Turk J Hemato
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
LETTERS TO EDITOR Turk J Hematol 20
Page 119 and 120:
LETTERS TO EDITOR Turk J Hematol 20
Page 121 and 122:
33 rd Volume Index / 33. Cilt Dizin
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129:
show all

Turkish Journal of Hematology Volume: 33 - Issue: 4

Create successful ePaper yourself

Delete template?

Save as template?